EUVIMEDEUVIMED entdecken
Crossref

Self‐microemulsifying drug delivery system‐based gastroretentive in situ raft of pazopanib with enhanced solubility and bioavailability

Vridhi Sachdeva, Anshula Mehra, Gurdeep Singh, Akshay Kumar, Pranesh Kumar, Gurpreet Singh, Neena Bedi iD

Archiv der Pharmazie · 2025-01 · 358 (1)

DOI: 10.1002/ardp.202400179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 24.10.2024. Verfasst von Vridhi Sachdeva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India. Hauptthemen laut MEDLINE: Biological Availability, Solubility, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pazopanib hydrochloride (PZH) is a Biopharmaceutics Classification System class II drug that faces challenges at the formulation forefront including low aqueous solubility (0.043 mg/mL) and poor oral bioavailability (14–39%). The present investigation aimed to develop a self‐microemulsifying drug delivery system (SMEDDS) of PZH using a blend of Capryol® 90, Labrasol®, and propylene glycol to improve its solubility. Furthermore, a sustained‐release SMEDDS‐based gastroretentive floating system was developed and optimized using the Central Composite Design approach of DoE. The optimized SMEDDS‐based in situ gelling raft, R‐SM‐PZH, exhibited minimal floating lag time (3.09 ± 0.8 s), optimal viscosity (1229.4 ± 20.9 cP) and density (0.327 ± 0.15 g/mL) as compared to other formulations under study. Additionally, R‐SM‐PZH was evaluated for its in vitro dissolution in FaSSGF and FeSSGF, pharmacokinetic profile, and MTT assay (against NCI‐H460 lung cancer cells) compared to pure PZH. A 12 h sustained release, three‐fold augmentation in dissolution rate and bioavailability, and 15‐fold enhancement in cytotoxicity were observed in comparison to pure PZH. Thus, the SMEDDS‐based in situ gelling raft presents a promising approach to advancing the developability potential of PZH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological AvailabilitySolubilityPyrimidinesSulfonamidesDrug Delivery SystemsEmulsionsIndazolesHumansAnimalsRatsCell Line, TumorDelayed-Action PreparationsDrug LiberationAdministration, OralMaleChemistry, PharmaceuticalRats, Sprague-Dawley

Stichwörter der Autor:innen

anticancercentral composite designgastroretentivepazopanib hydrochlorideself‐microemulsifying drug delivery system

Substanzen

PyrimidinesSulfonamidesEmulsionspazopanibIndazolesDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India.
  • Department of Botanical and Environmental Sciences, Guru Nanak Dev University, Amritsar, India.

ORCID-Profile: Neena Bedi

Förderung

  • None

Zitieren

APA

Sachdeva, V., Mehra, A., Singh, G., Kumar, A., Kumar, P., Singh, G., & Bedi, N. (2025). Self‐microemulsifying drug delivery system‐based gastroretentive in situ raft of pazopanib with enhanced solubility and bioavailability. Archiv der Pharmazie, 358(1). https://doi.org/10.1002/ardp.202400179

Vancouver

Sachdeva V, Mehra A, Singh G, Kumar A, Kumar P, Singh G, et al. Self‐microemulsifying drug delivery system‐based gastroretentive in situ raft of pazopanib with enhanced solubility and bioavailability. Archiv der Pharmazie. 2025;358(1). doi:10.1002/ardp.202400179

BibTeX
@article{Sachdeva2025,
  author = {Sachdeva, Vridhi and Mehra, Anshula and Singh, Gurdeep and Kumar, Akshay and Kumar, Pranesh and Singh, Gurpreet and Bedi, Neena},
  title = {Self‐microemulsifying drug delivery system‐based gastroretentive in situ raft of pazopanib with enhanced solubility and bioavailability},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {1},
  doi = {10.1002/ardp.202400179}
}
Kostenlos starten →